在长期疾病修改帕金森病试验的结果测量中嵌入患者输入
Cristina Gonzalez-Robles1, Michèle Bartlett2, Matthew Burnell3
1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Movement disorders : official journal of the Movement Disorder Society
|December 23, 2023
概括
运动障碍学会赞助的统一帕金森病评分表 (MDS-UPDRS) 部分I + II总和评分的修订是长期帕金森病试验的首选结果.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 患者报告的结果
背景情况:
- 对帕金森病 (PD) 的有效临床试验需要有效,响应和与患者相关的结果措施.
- 选择适当的初级结果措施对于评估PD疾病修饰疗法至关重要.
研究的目的:
- 在帕金森病中确定和选择以患者为中心的初级结果测量方法,用于长期 (3+年) 疾病修饰试验.
- 确保所选择的结果措施反映了患者的优先事项,并适合临床试验使用.
主要方法:
- 一个多学科专家小组 (神经学,统计学,健康经济学) 审查了潜在的结果措施.
- 患者与公众参与和参与 (PPIE) 代表提供了关于患者相关性和考虑的关键投入.
- 可行性,临床特征和患者相关性被系统评估和合成.
主要成果:
- 运动障碍学会赞助的统一帕金森病评级表 (MDS-UPDRS) 第三部分的修订最初被考虑.
- 可行性和临床特征有利于MDS-UPDRS第II部分,但PPIE输入强调了非运动症状的重要性.
- 最终的选择是MDS-UPDRS部分I + II总分,包括与患者相关的运动和非运动方面.
结论:
- 建议MDS-UPDRS部分I + II总分作为帕金森病大规模3年疾病修饰试验的主要结果指标.
- 这种选择优先考虑以患者为中心,包括运动和非运动症状,这对于长期试验评估至关重要.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
Parkinson's Disease: Overview
554
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
554


